来自权威媒体报道： https://www.reuters.com/article/us-health-coronavirus-europe-vaccines/eu-reviews-jj-covid-19-vaccine-for-blood-clots-expands-astrazeneca-probe-idUSKBN2BW1MB?il=0https://www.bloomberg.com/news/articles/2021-04-09/eu-regulator-investigating-blood-clots-after-j-j-covid-vaccinehttps://www.ft.com/content/ddd8ec03-450c-4a14-b1e2-e3afe1f44c7b EMA investigates potential link between Johnson & Johnson vaccine and blood clots Donato Paolo Mancini in Rome and Hannah Kuchler in London The European Medicines Agency is probing a potential causal link between four “serious cases of unusual blood clots” with a low platelet count and the Johnson & Johnson coronavirus vaccine. The EMA made the disclosure on Friday, noting that the vaccine is only being used in the US. “One case occurred in a clinical trial and three cases occurred during the vaccine rollout in the USA,” the regulator said. “One of them was fatal.” It added it was “currently not clear whether there is a causal association” between the shot and the adverse event. J&J said it was working with experts and regulators to assess the data. “Our close tracking of side effects has revealed a small number of very rare events following vaccination,” it said. “At present, no clear causal relationship has been established between these rare events and the Janssen Covid-19 vaccine.” New York-listed shares in the drug maker edged 0.4 per cent lower. Earlier this week, the EMA said that blood clots in the brain, coupled with low platelet counts and bleeding, should be listed as a very rare side effect of the Oxford/AstraZeneca shot. The UK and other countries have restricted its use to older patients only. The J&J and AstraZeneca vaccines use the same type of technology, using a viral vector to spur the immune system to fend off the virus that causes Covid-19. The J&J shot, administered in one dose, was approved for use in Europe last month, but rollout has not begun yet. The EMA also on Friday said it had begun probing whether capillary leak syndrome, in which fluid leaks from blood vessels causing a drop in blood pressure and tissue swelling, was causally linked to the AstraZeneca shot. The regulator said it had received reports of five such cases.
EMA investigates potential link between Johnson & Johnson vaccine and blood clots Donato Paolo Mancini in Rome and Hannah Kuchler in London
The European Medicines Agency is probing a potential causal link between four “serious cases of unusual blood clots” with a low platelet count and the Johnson & Johnson coronavirus vaccine. The EMA made the disclosure on Friday, noting that the vaccine is only being used in the US. “One case occurred in a clinical trial and three cases occurred during the vaccine rollout in the USA,” the regulator said. “One of them was fatal.”
It added it was “currently not clear whether there is a causal association” between the shot and the adverse event.
J&J said it was working with experts and regulators to assess the data. “Our close tracking of side effects has revealed a small number of very rare events following vaccination,” it said. “At present, no clear causal relationship has been established between these rare events and the Janssen Covid-19 vaccine.”
New York-listed shares in the drug maker edged 0.4 per cent lower.
Earlier this week, the EMA said that blood clots in the brain, coupled with low platelet counts and bleeding, should be listed as a very rare side effect of the Oxford/AstraZeneca shot. The UK and other countries have restricted its use to older patients only.
The J&J and AstraZeneca vaccines use the same type of technology, using a viral vector to spur the immune system to fend off the virus that causes Covid-19.
The J&J shot, administered in one dose, was approved for use in Europe last month, but rollout has not begun yet.
The EMA also on Friday said it had begun probing whether capillary leak syndrome, in which fluid leaks from blood vessels causing a drop in blood pressure and tissue swelling, was causally linked to the AstraZeneca shot. The regulator said it had received reports of five such cases.
系统提示：若遇到视频无法播放请点击下方链接
https://www.youtube.com/embed/HtWRcK-W2LA 美国也有shut down
随年龄降低 风险急剧增大 老人则几乎毫无问题
而最前线年轻医护打疫苗的时候牛津还没批，辉瑞批了。所以牛津一上来的时候几乎都是给老人打。慢慢才降低年龄的bar.
所以问题才surface的这么晚
而欧洲拿到牛津疫苗后，很多地方拿来给老师打，这么一打就暴露问题了。
这个review只是保险起见 不能就说强生有问题 强生和牛津用的腺病毒不一样 说不定是牛津的黑猩猩病毒有问题
英国数据是打疫苗4日到4周出现这种血栓的都有
我个人认为你们停强生现在还是为了保险起见吧 毕竟美国的其他疫苗供货还挺足的
那时候默多克旗下的保守派报纸带的风向 把这个saga和脱欧主义联系到一起
现在数据拿出来了 牛津疫苗出现这种血栓是其他疫苗（就是辉瑞）的五十倍 五十倍。。。 这的确不是一个可以忽视的对比了
再等一阵在下结论吧，如果最后证实就是百万分之一的概率的话，好像也不比背景发病率高太多。腺病毒疫苗可以理解成劣化的mRNA疫苗，出问题概率更高也是正常的。
我估计这个数据，牛津疫苗的可能不会有 至少不会在发达国家里面有了 强生可能还会有
现在欧洲都把三十岁以下的牛津疫苗给禁止了。英国也有说法说实际上会给尽量给40以下都不打牛津。 可能只有第三世界没得选的会硬头皮给30岁以下打。昨天有那种小岛国的人到BBC上说，这消息英国政府宣布的太鲁莽了bla bla,我们这里到处都是年轻人，只买了牛津，你让我们咋整。。。
目前欧洲的数据，20-29岁牛津疫苗的严重血栓反应是十万分之一。
我还是希望最好不是腺病毒疫苗的问题，就是牛津自己拉垮了。否则这些第三世界靠mRNA推广很难啊。
现在问题是只有发达国家才有能力跟信誉做可靠的跟踪调查吧。。 在什么莫桑比克埃塞俄比亚那些国家有啥数据？ 就跟灭活疫苗只有HK有不良反应数据一样--当然HK也有复辟太的数据不是只针对科兴哦。